COMPARE THE EVIDENCE

Semaglutide

Findings, possible implications, and reported experiences.

About Semaglutide

PeptideMetabolism

Primary research area: Emerging research
Regulatory status: Research status varies
Evidence level: Evidence level not yet characterized
Primary mechanism: Mechanism not yet characterized

Reference profile available · Coverage varies by section

Also known as Ozempic · Wegovy · Rybelsus

Semaglutide is a GLP-1 receptor agonist. It helps regulate blood glucose by increasing insulin release and reducing glucagon when glucose is high. [1]

What has been observed?

Selected source-linked reading notes, not the complete literature or a pooled conclusion.

Human · Reading scope not recorded

What did semaglutide achieve in the direct comparison?

72 weeks; maximum tolerated semaglutide 1.7/2.4 mg versus tirzepatide 10/15 mg; adults without diabetes.

Participants assigned semaglutide lost an average of 13.7% of body weight at 72 weeks, versus 20.2% with tirzepatide.

Limits: This result applies to the studied regimens and population. Weight change does not establish preservation of muscle or long-term cardiovascular benefit.

Open primary source · Read interpretation separately

Human · Abstract reviewed

What did the direct comparison with liraglutide show?

338 adults; semaglutide 2.4 mg weekly versus liraglutide 3 mg daily.

Mean weight reduction was 15.8% with semaglutide and 6.4% with liraglutide at 68 weeks.

Limits & adverse findings: Open-label comparison in adults without diabetes; other doses and outcomes need separate evidence. Gastrointestinal events were common in both groups.

Open primary source · Read interpretation separately

Explore outcomes for this compound

Uses & research: The cited Ozempic label covers type 2 diabetes and specific cardiovascular and kidney-risk indications. Uses depend on the branded product and patient population. [1]
Known half-life: Approximately 1 week in the Ozempic injection label. This is a drug-elimination estimate, not the time until every effect stops. [1]
Half-life describes how quickly the measured drug concentration falls by half. It does not set a dosing interval.
Evidence & important limits: This profile uses the Ozempic label, not every semaglutide formulation. Important label warnings include gastrointestinal reactions, pancreatitis and thyroid C-cell tumors observed in rodents. [1]

Safety & evidence boundaries

Source-specific information, not a personal safety clearance or monitoring plan.

Label safety signals

The current Ozempic label lists gastrointestinal reactions, pancreatitis, diabetic-retinopathy complications, severe gastrointestinal reactions, gallbladder disease, kidney injury from fluid loss, hypersensitivity and aspiration risk around anesthesia. These are label warnings, not a personalized risk estimate.

Source 1: Ozempic prescribing information

Human study: Gastrointestinal events were common in both groups. Source

Explore safety questions by system

These are literature filters, not claims that this compound causes each effect. A keyword match is not a confirmed adverse reaction.

Heart, blood pressure & lipids Liver injury Kidney function Glucose effects Reproductive & endocrine effects Mood & sleep Adverse effects & interactions

Interactions, rare harms, long-term effects and reversibility require separate evidence. Do not infer they are absent when the sources here do not address them.

Identity, names & formulations

Canonical compound: Semaglutide · semaglutide

Searchable names: Ozempic, Wegovy, Rybelsus

Names share a parent research page. Different esters, salts, routes and brands are not assumed to have the same half-life, indication or exposure.

Combination evidence stays attached to the studied combination. It is not automatically assigned to each ingredient.

Understand the evidence types

Read the model and design first, then the population, outcome and limitations. These categories describe evidence, not a best-compound ranking.

Randomized human trials: Compare assigned interventions. Randomization does not by itself establish low bias or relevance to every population.
Controlled human studies: Use a comparison group; allocation and confounding still matter.
Prospective human research: Follows participants forward. It may be observational or interventional, so this is not a separate quality grade.
Observational human research: Describes associations. Confounding can explain differences.
Case reports and series: Useful for unusual events and safety signals, not reliable rates or effect sizes.
Animal research: Can test biology and function in a living model. Human exposure, benefit and safety remain separate questions.
Cell and tissue research: Tests responses in a preparation, including human-derived cells. It is not a human participant trial.
Mechanistic and computational evidence: Helps explain or predict a pathway; predictions need experimental and clinical testing.
Anecdotal reports: Self-reported experiences can generate questions. Product identity, selection bias and other interventions may be uncontrolled.

Systematic reviews synthesize studies and depend on their quality. Preprint status and abstract versus full-paper reading are separate labels. Citation popularity measures attention, not reliability. A study summary is not a formal quality appraisal.

Sources for this profile

1. Ozempic prescribing information Drug label · indications, warnings and clinical pharmacology

Reference facts checked 2026-09-16. Source scope is listed above; this is not a formal quality appraisal. See each label for full prescribing information.

Browse all studies

Research outcomeResearch model

Study model describes the source. Confidence depends on methods, replication, population and outcome.

Loading compound research…